NovImmune Inks Antibody Licensing Agreement With Genentech
As per the terms of the agreement NovImmune is expected to get an upfront payment and is eligible to receive clinical milestones and royalties on sales. NovImmune said
Amgen has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Repatha (evolocumab) supporting its broader use prior to a first heart attack or stroke.
Oracle claimed that the new solution helps pharmaceutical manufacturers facilitate compliance with emerging electronic pedigree (ePedigree) initiatives and regulatory requirements, reduce business and reputational risk associated with the